Published in AIDS Weekly, October 24th, 2005
Following the closing of these agreements, XTLbio has an exclusive license to VivoQuest's intellectual property and technology, including promising hepatitis C virus (HCV) compounds and VivoQuest's proprietary compound library.
In connection with the closing, XTL Biopharmaceuticals (XTLbio) made an up-front payment of approximately $1.4 million, which was satisfied through the issuance to VivoQuest of approximately 1.3 million XTLbio ordinary shares. All other amounts to be paid to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.